US 340B drug pricing program disputes

The 340B Drug Pricing Program, which requires pharmaceutical manufacturers to provide discounted outpatient drugs to safety-net healthcare organizations, is facing increased regulatory and legal challenges.

While the program has historically supported community services such as mental health clinics and diabetes education for uninsured and low-income patients, recent developments indicate growing friction between government agencies and healthcare providers. An internal analysis from the U.S. Department of Health and Human Services (HHS) suggests the program may now be incentivizing the overuse of expensive medications and encouraging hospital consolidation.

In response to proposed changes, the American Hospital Association (AHA) has filed a federal lawsuit to block a pilot program scheduled for January 1, 2027. This pilot aims to transition the 340B model from upfront discounts to an after-the-fact rebate system for 25 high-cost drugs covered under Medicare. The AHA contends that the government has not adequately addressed the administrative and operational burdens placed on hospitals that would be required to pay full market prices upfront.